Cite

HARVARD Citation

    Pope, J. et al. (2019). Persistence of Tofacitinib in the Treatment of Rheumatoid Arthritis in Open‐Label, Long‐Term Extension Studies up to 9.5 Years. ACR open rheumatology. 1 (2), pp. 73-82. [Online]. 
  
Back to record